May 2012

Agile Sciences receives a $257,000 Phase I NIH SBIR Award to evaluate the ability of Agile Sciences' compounds to enhance the efficacy of antiseptic products. News release.

April 2012

Agile Sciences is awarded a $1M Phase II SBIR grant from the National Institutes of Health to advance Agile Sciences' treatment for dental caries. News release.

February 2012

An Agile Sciences molecule is shown to enhance the efficacy of carbapenem antibiotics against a NDM-1-producing Klebsiella "superbug". News release.

October 2011

Agile Sciences receives NIH STTR grant to evaluate anti-biofilm compounds for treating cystic fibrosis in collaboration with Dr. Richard Boucher at UNC Chapel Hill. News release.

More News...

Agile Sciences founders John Cavanagh and Christian Melander analyze the results of anti-biofilm screening tests.

The co-founders of Agile Sciences have developed compounds that can disperse colonies of bacteria called biofilms. These compounds have applications in the areas of medicine, agriculture, and industry.

Biofilms that form in the human body are up to ten thousand times more resistant to antibiotics and immune systems than free-floating bacteria, making them very difficult to treat medically. In agriculture, every year billions of dollars of crops are lost due to the formation of biofilms. Industrial needs for effective biofilm dispersion include surface coatings and cleansing products.

Agile Sciences' technology addresses problems associated with biofilm formation through the use of proprietary non-toxic organic compounds.